NCT06907329Completed

The Impact of Nicotinamide Mononucleotide Sustained-release Tablets on Immunosenescence and Metabolism in Middle-aged and Elderly Individuals With Metabolic Disorders.

Source: ClinicalTrials.gov · Last updated 3 Nov 2026

Brief summary (registry, in English)

This study evaluates whether nicotinamide mononucleotide (NMN) sustained-release tablets affect markers of immune system aging in adults aged 50 to 70 years with overweight or obesity and metabolic disorders. It compares NMN, 1,000 mg once daily for 26 weeks, with a matching placebo. The main assessment is the change from baseline in the proportion of a blood T-cell population associated with immune system aging. The study also evaluates liver fat, blood sugar regulation, body composition, other immune and metabolic markers, and cardiorespiratory fitness, together with laboratory measures of safety.

Status (registry): Completed
Study type: Interventional
Enrollment: 124 (actual)
First submitted: 19 Mar 2025
Start date: 5 Jun 2025
Primary completion date: 18 Oct 2026
Lead sponsor: Qing Su
Diseases: Obesity, Fatty liver disease (MASLD/MASH), Type 2 diabetes
NCT number: NCT06907329

What you commit to

Study type: Interventional
Participants enrolled: 124
From 5 Jun 2025 to the primary completion date, 18 Oct 2026
1 site in 1 country
Visits and tests: ask the trial team, the registry does not list them

Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.

Who cannot take part

Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.

Other illness

(2) Patients with autoimmune diseases (excluding Hashimoto's thyroiditis);
(3) Severe cardiovascular disease or cardiac insufficiency;
(5) Chronic obstructive pulmonary disease;
(6) Chronic active hepatitis or cirrhosis;
(7) Chronic renal insufficiency;
(8) Stroke patients;
(9) Severe haematological diseases;
(10) Infectious diseases;
(11) Mental illness;
(12) Other conditions that, in the opinion of the investigator, may affect the results of the study;

Lab values

(15) ALT, AST values are more than three times higher than the upper limit of the normal reference range;

Other

(1) Patients with tumours;
(4) Systolic blood pressure \> 160 mmHg or diastolic blood pressure \> 100 mmHg;
(13) Those who have used NMN or other anti-aging agents within six months;
(14) Premenopausal women;

Who the study is looking for

(1) Age 50-70 years with overweight or obesity (BMI ≥ 24 kg/m²);
(2) At least one of the following three: metabolism-related fatty liver disease (diagnosed by ultrasound); pre-diabetes; type 2 diabetes mellitus with HbA1c \<7% without glucose-lowering drug therapy;
(3) Agreed to participate in the trial and could adhere to the follow-up and visit the hospital on their own; signed the informed consent form.

Age in the registry: 50 years to 70 years · Sex: All · Does not accept healthy volunteers

Full criteria on ClinicalTrials.gov

Sites (1)

Sites in registry order. Pick your city on the disease page to sort them by distance.

Site	City	Country	Site status
Xin Hua Hospital Affiliated to Shanghai Jiao Tong University School of Medicine Coordinator of this site? Confirm its status	Shanghai	China	Unknown status

This page is information, not medical advice. Discuss any trial with your doctor.